N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.
暂无分享,去创建一个
Wolfgang Friess | Fritz Sörgel | F. Sörgel | W. Friess | Andreas Seidl | Fabian Higel | Andreas Seidl | Fabian Higel
[1] Brittney Livingston,et al. Real‐time product attribute control to manufacture antibodies with defined N‐linked glycan levels , 2015, Biotechnology progress.
[2] C. Milstein,et al. Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.
[3] Lawrence W. Dick,et al. Isomerization in the CDR2 of a monoclonal antibody: Binding analysis and factors that influence the isomerization rate , 2010, Biotechnology and bioengineering.
[4] R. Bischoff,et al. Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology. , 1994, Journal of chromatography. B, Biomedical applications.
[5] Wolfgang Lindner,et al. Comparison of hydrophilic-interaction, reversed-phase and porous graphitic carbon chromatography for glycan analysis. , 2011, Journal of chromatography. A.
[6] Miss A.O. Penney. (b) , 1974, The New Yale Book of Quotations.
[7] Lai-Xi Wang,et al. Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor. , 2011, Journal of the American Chemical Society.
[8] Gregory C Flynn,et al. Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry. , 2007, Analytical biochemistry.
[9] K. Shitara,et al. The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.
[10] Johannes Kneer,et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. , 2007, Glycobiology.
[11] C. Ries,et al. GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab , 2012, Clinical Cancer Research.
[12] Ming Li,et al. Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms* , 2008, Journal of Biological Chemistry.
[13] P. Parren,et al. Online nanoliquid chromatography-mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis. , 2012, Analytical biochemistry.
[14] J. M. Beals,et al. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. , 2005, Analytical chemistry.
[15] David Passmore,et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor , 2006, Nature Biotechnology.
[16] M Goodall,et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. , 2000, Molecular immunology.
[17] B. Kabakoff,et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.
[18] Stacey Ma,et al. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. , 2008, Biologicals : journal of the International Association of Biological Standardization.
[19] B. Domon,et al. Capillary electrophoresis/electrospray ion trap mass spectrometry for the analysis of negatively charged derivatized and underivatized glycans. , 2002, Rapid communications in mass spectrometry : RCM.
[20] Yang Wang,et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. , 2011, Molecular immunology.
[21] Andrew M Goetze,et al. Rates and impact of human antibody glycation in vivo. , 2012, Glycobiology.
[22] Stephen P. Young,et al. Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding* , 2001, The Journal of Biological Chemistry.
[23] Qiang Qin,et al. High-throughput immunoglobulin G N-glycan characterization using rapid resolution reverse-phase chromatography tandem mass spectrometry. , 2009, Analytical biochemistry.
[24] Lora Hamuro,et al. The Impact of Glycosylation on the Pharmacokinetics of a TNFR2:Fc Fusion Protein Expressed in Glycoengineered Pichia Pastoris , 2012, Pharmaceutical Research.
[25] S. Cohen,et al. Antibody structure , 2006 .
[26] Wei Wang,et al. Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.
[27] O. Salas-Solano,et al. On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies. , 2008, Analytical chemistry.
[28] Alain Beck,et al. GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins , 2010, Expert opinion on drug discovery.
[29] Janice M. Reichert,et al. Marketed therapeutic antibodies compendium , 2012, mAbs.
[30] Huijuan Li,et al. Pharmacological significance of glycosylation in therapeutic proteins. , 2009, Current opinion in biotechnology.
[31] Naoyuki Taniguchi,et al. Capillary electrophoresis-electrospray ionization mass spectrometry for rapid and sensitive N-glycan analysis of glycoproteins as 9-fluorenylmethyl derivatives. , 2008, Glycobiology.
[32] D. Harvey,et al. Reversed-phase ion-pairing liquid chromatography/ion trap mass spectrometry for the analysis of negatively charged, derivatized glycans. , 2003, Rapid communications in mass spectrometry : RCM.
[33] R. Bass,et al. N-terminal Glutamate to Pyroglutamate Conversion in Vivo for Human IgG2 Antibodies , 2011, The Journal of Biological Chemistry.
[34] P. Bondarenko,et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. , 2011, Glycobiology.
[35] P. Sun,et al. Recognition of immunoglobulins by Fcgamma receptors. , 2002, Molecular immunology.
[36] R. Stockert,et al. The asialoglycoprotein receptor: relationships between structure, function, and expression. , 1995, Physiological reviews.
[37] Roy Jefferis,et al. Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.
[38] F. Sörgel,et al. N-glycan PK Profiling Using a High Sensitivity nanoLCMS Work-Flow with Heavy Stable Isotope Labeled Internal Standard and Application to a Preclinical Study of an IgG1 Biopharmaceutical , 2015, Pharmaceutical Research.
[39] M. Lieber,et al. The Mechanism of Human Nonhomologous DNA End Joining* , 2008, Journal of Biological Chemistry.
[40] Reb J. Russell,et al. Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping. , 2011, Journal of chromatography. A.
[41] Shigeru Iida,et al. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.
[42] R. Bayer,et al. The impact of glycosylation on monoclonal antibody conformation and stability , 2011, mAbs.
[43] M. Nussenzweig,et al. Mannose Receptor-Mediated Regulation of Serum Glycoprotein Homeostasis , 2002, Science.
[44] Zhongqi Zhang,et al. Naturally occurring glycan forms of human immunoglobulins G1 and G2. , 2010, Molecular immunology.
[45] Akira Okazaki,et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.
[46] A. Deelder,et al. Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins. , 2008, Analytical chemistry.
[47] T. Raju,et al. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.
[48] Wolfgang Lindner,et al. HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals , 2010, Analytical and bioanalytical chemistry.
[49] Douglas S Rehder,et al. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. , 2005, Analytical chemistry.
[50] R. Hansen,et al. Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.
[51] Ilja Ritamo,et al. Nanoscale reversed-phase liquid chromatography–mass spectrometry of permethylated N-glycans , 2013, Analytical and Bioanalytical Chemistry.
[52] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[53] Samuel Moser,et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II , 2006, Biotechnology and bioengineering.
[54] P. Sun,et al. Recognition of immunoglobulins by Fcγ receptors , 2002 .
[55] Capillary electrophoresis-mass spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals , 2011, Analytical and bioanalytical chemistry.
[56] Damian Houde,et al. Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding* , 2010, Molecular & Cellular Proteomics.
[57] Marcella Yu,et al. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans , 2012, mAbs.
[58] Hongcheng Liu,et al. Heterogeneity of monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.
[59] Randal R Ketchem,et al. Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype , 2008, Electrophoresis.
[60] F. Sörgel,et al. Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins , 2014, mAbs.
[61] Jean-Luc Teillaud,et al. Impact of Glycosylation on Effector Functions of Therapeutic IgG † , 2010, Pharmaceuticals.
[62] S. Akilesh,et al. FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.
[63] J. Hochman,et al. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials. , 2011, Biologicals : journal of the International Association of Biological Standardization.
[64] S. Iida,et al. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.
[65] K. Anumula. New high-performance liquid chromatography assay for glycosyltransferases based on derivatization with anthranilic acid and fluorescence detection. , 2012, Glycobiology.
[66] M. Newkirk,et al. Differential clearance of glycoforms of IgG in normal and autoimmune‐prone mice , 1996, Clinical and experimental immunology.
[67] Thomas M. Dillon,et al. Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass* , 2008, Journal of Biological Chemistry.
[68] H. Spiegelberg,et al. The carbohydrate contents of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses. , 1968, Biochemistry.
[69] F. Sörgel,et al. Reversed-phase liquid-chromatographic mass spectrometric N-glycan analysis of biopharmaceuticals , 2013, Analytical and Bioanalytical Chemistry.
[70] A. Deelder,et al. Normal-phase nanoscale liquid chromatography-mass spectrometry of underivatized oligosaccharides at low-femtomole sensitivity. , 2004, Analytical chemistry.
[71] Hongcheng Liu,et al. Disulfide bond structures of IgG molecules , 2012, mAbs.
[72] Heide Kogelberg,et al. Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy. , 2007, Glycobiology.
[73] David Ouellette,et al. Increased serum clearance of oligomannose species present on a human IgG1 molecule , 2012, mAbs.
[74] Akira Okazaki,et al. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics. , 2007, Journal of biotechnology.
[75] Stuart M Haslam,et al. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. , 2012, Nature chemical biology.
[76] Kurt Forrer,et al. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. , 2008, Biologicals : journal of the International Association of Biological Standardization.
[77] Hai Pan,et al. C‐terminal lysine processing of human immunoglobulin G2 heavy chain in vivo , 2011, Biotechnology and bioengineering.
[78] S. Iida,et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model , 2008, Cancer Immunology, Immunotherapy.
[79] D. Aswad,et al. Isoaspartate in peptides and proteins: formation, significance, and analysis. , 2000, Journal of pharmaceutical and biomedical analysis.
[80] Lihua Huang,et al. Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. , 2006, Analytical biochemistry.
[81] K R Anumula,et al. High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid. , 1998, Glycobiology.
[82] R. Ghirlando,et al. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. , 2001, The Journal of biological chemistry.
[83] Hongcheng Liu,et al. Glutamine deamidation of a recombinant monoclonal antibody. , 2008, Rapid communications in mass spectrometry : RCM.
[84] G. Gregoriadis,et al. The role of sialic acid in determining the survival of glycoproteins in the circulation. , 1971, The Journal of biological chemistry.
[85] G. Ashwell,et al. Carbohydrate-specific receptors of the liver. , 1982, Annual review of biochemistry.
[86] T. Wurch,et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. , 2008, Current pharmaceutical biotechnology.
[87] K. Kuma,et al. The Complete Nucleotide Sequence of the Human Immunoglobulin Heavy Chain Variable Region Locus , 1998, The Journal of experimental medicine.
[88] S. Gordon,et al. The mannose receptor: linking homeostasis and immunity through sugar recognition. , 2005, Trends in immunology.
[89] P. Allavena,et al. From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. , 2004, Critical reviews in immunology.
[90] Gregory C Flynn,et al. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. , 2008, Glycobiology.
[91] J. Prestegard,et al. NMR Analysis Demonstrates Immunoglobulin G N-glycans are Accessible and Dynamic , 2011, Nature chemical biology.
[92] Eric Ezan,et al. Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. , 2009, Bioanalysis.
[93] C. Klein,et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.
[94] M. Retter,et al. Impact of Glycation on Antibody Clearance , 2014, The AAPS Journal.
[95] R. Huber,et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.